Versuchen GOLD - Frei
TELANGANA WAGES WAR AGAINST COUNTERFEIT DRUGS
Bio Spectrum
|BioSpectrum India Oct 2024
Telangana contributes nearly one-third to India’s production and one-fifth to its exports in the pharmaceutical sector.

Hyderabad is a home to 800 pharma companies and life sciences capital of the country. To make the state free of spurious drugs, the Drugs Control Administration (DCA), Telangana is working relentlessly to detect spurious drugs movement in the market. In 2023 the DCA has carried out 26,133 inspections and taken action in 4984 cases with 4991 cases of violations. In the first four months of this year till April 2024 DCA has carried out 8495 inspections and found out that 50 drugs are ‘Not of Standard Quality’ (NSQ). Let’s look at how DCA is continuing its crusade against the spurious drugs issue and keep the public health of the state in order.
From the beginning of 2024, the DCA of Telangana, under the leadership of Director General (DG) V B Kamalasan Reddy, (who took charge as DG in July 2023) has intensified its efforts to combat the menace of spurious, fake and NSQ in the state. In the past few months, the DCA has targeted nearly 100 facilities across the state, resulting in the confiscation of 4000 to 5000 kgs of counterfeit medications worth Rs 50-60 crore. These recent raids have uncovered a widespread network of spurious drugs, highlighting the ongoing battle against counterfeit medications that pose a severe threat to public health.
Highlighting the efforts taken by the DCA of Telangana, Kamalasan Reddy said that he is committed to ensuring that quality, efficacy, and safety of medicines being supplied to the people in the state. “As part of this objective, we at the DCA have set our goals and accordingly devised plans for inspecting pharmaceutical companies, medical shops, medical device manufacturing companies, and blood banks across the state,” said Kamalasan Reddy.
Emerging pharmaceutical hub
Diese Geschichte stammt aus der BioSpectrum India Oct 2024-Ausgabe von Bio Spectrum.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Bio Spectrum

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size